| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Operating income (loss) from continuing operations | 2,809,766 | - |
| Change in fair value of warrant liability | -10,303,657 | -10,302,657 |
| Warrant issuance costs | 10,420,982 | 10,420,982 |
| Operating income from continuing operations | - | 3,732,489 |
| Gain on asset disposition and vivus settlement | 6,973,302 | 6,973,302 |
| Employee stock-based compensation | 229,496 | 154,359 |
| Prepaid expenses and other current assets | 62,317 | 74,457 |
| Accounts payable | -343,193 | 205,690 |
| Accrued expenses | 412,388 | 160,983 |
| Net cash used in operating activities - continuing operations | -3,809,837 | -2,675,913 |
| Net cash (used in) provided by operating activities - discontinued operations | -1,991,326 | -1,991,326 |
| Net cash used in operating activities | -5,801,163 | -4,667,239 |
| Proceeds from common stock and prefunded warrants, net | 8,503,018 | 8,503,018 |
| Redemption of series a preferred stock | 341,560 | 224,249 |
| Net cash provided by (used in) financing activities - continuing operations | 8,161,458 | 8,278,769 |
| Net cash provided by (used in) financing activities | 8,161,458 | 8,278,769 |
| Net increase (decrease) in cash | 2,360,295 | 3,611,530 |
| Cash and cash equivalents at beginning of period | 3,709,971 | - |
| Cash and cash equivalents at end of period | 6,070,266 | - |
Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc. (PTPI)